Effects of ranibizumab (Lucentis ®) and bevacizumab (Avastin®) on human corneal endothelial cells

Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are ...
Source: BMC Ophthalmology - Category: Opthalmology Authors: Tags: Research article Source Type: research